SAN FRANCISCO – Moderna Therapeutics Inc. CEO Stéphane Bancel opened the 35th annual J.P. Morgan Healthcare Conference on Monday by unblinding indications and targets for a raft of before-now veiled candidates in the mRNA specialist's pipeline, five of which are now in the clinic, including its Astrazeneca plc-partnered cardiometabolic candidate, AZD-8601.